Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents

Journal of Medicinal Chemistry

Volumn 59, Issue 13, 2016, Pages 6387-6406

  Montanari, Serena ^a   Scalvini, Laura ^b   Bartolini, Manuela ^a   Belluti, Federica ^a   Gobbi, Silvia ^a   Andrisano, Vincenza ^a   Ligresti, Alessia ^c   Di Marzo, Vincenzo ^c   Rivara, Silvia ^b   Mor, Marco ^b   Bisi, Alessandra ^a   Rampa, Angela ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 [ [[(2 OXO 2H CHROMEN 7 YL)OXY]METHYL] 1H 1,2,3 TRIAZOL 1YL)PHENYL HEPTYLCARBAMATE; 3 [4 [[(2 OXO 2H CHROMEN 7 YL)OXY]METHYL] 1H 1,2,3 TRIAZOL 1YL]PHENYL(5 PHENYLPENTYL)CARBAMATE; 3 [[4 [[(2 OXO 2H CHROMEN 7 YL)OXY]METHYL] 1H 1,2,3 TRIAZOL 1YL]METHYL]PHENYL HEPTYLCARBAMATE; 3 [[4 [[(2 OXO 2H CHROMEN 7 YL)OXY]METHYL] 1H 1,2,3 TRIAZOL 1YL]METHYL]PHENYL(PHENYLPENTYL)CARBAMATE; 3 [[METHYL [3 [[2 OXO 3 PHENYL 2H CHROMEN 7 YL)OXY]PROPYL]AMINO]METHYL]PHENYL(5 PHENYLPENTYL)CARBAMATE; 3 [[METHYL [5 [(2 OXO 2H CHROMEN 7 YL)OXY]PENTYL]AMINO]METHYL]PHENYL HEPTYLCARBAMATE; 3 [[METHYL [5 [(2 OXO 2H CHROMEN 7 YL)OXY]PENTYL]AMINO]METHYL]PHENYL(5PHENYLPENTYL)CARBAMATE; 3 [[METHYL [5 [(5 OXO 5H CHROMENO[2,3 B]PYRIDI 8 YL)OXY]PENTYL]AMINO]METHYL]PHENYL HEPTYLCARBAMATE; 3 [[METHYL [5 [(5 OXO 5H CHROMENO[2,3 B]PYRIDIN 8 YL)OXY]PENTYL]AMINO]METHYL]PHENYL HEPTYLCARBAMATE; 3 [[METHYL[3 [(2 OXO 2H CHROMEN 7 YL)OXY]PROPYL]AMINO]METHYL]PHENYL HEPTYLCARBAMATE; 3 [[METHYL[3 [(2 OXO 2H CHROMEN 7 YL)OXY]PROPYL]AMINO]METHYL]PHENYL(4 HEXYLPHENYL)CARBAMATE; 3 [[METHYL[3 [(2 OXO 2H CHROMEN 7 YL)OXY]PROPYL]AMINO]METHYL]PHENYL(6 PHENYLHEXYL)CARBAMATE; 3 [[METHYL[3 [(4 METHYL 2 OXO 2H CHROMEN 7 YL)OXY]PROPYL]AMINO]METHYL]PHENYL(5 PHENYLPENTYL)CARBAMATE; 3 [[METHYL[3 [(5 OXO 5H CHROMENO[2,3 B]PYRIDIN 8 YL)OXY]PROPYL]AMINO]METHYL)PHENYL HEPTYLCARBAMATE; 3 [[METHYL[3 [(6 OXO 6H BENZO[C]CHROMEN 3 YL)OXY]PROPYL]AMINO]METHYL]PHENYL(5 PHENYLPENTYL)CARBAMATE; 3 [[METHYL[3 [(6 OXO 7,8,9,10 TETRAHYDRO 6H BENZO[C]CHROMEN 3YL)OXY)PROPYL]AMINOMETHYL]PHENYL HEPTYLCARBAMATE; 3 [[METHYL[3 [(6 OXO 7,8,9,10 TETRAHYDRO 6H BENZO[C]CHROMEN-3YL)OXY]PROPYL]AMINO]METHYL]PHENYL(5 PHENYLPENTYL)CARBAMATE; 3 [[[3 [[3 (4 CHLOROPHENYL) 2 OXO 2H CHROMEN 7 YL]OXY]PROPYL](METHYL)AMINO]METHYL]PHENYL(5 PHENYLPENTYL)CARBAMATE; 3 [[[3 [[3 (4 METHOXYPHENYL) 2 OXO 2H CHROMEN 6 YL]OXY]PROPYL)(METHYL)AMINO]METHYL]PHENYL(5 PHENYLPENTYL)CARBAMATE; 3 [[[3 [[3 (4 METHOXYPHENYL) 2 OXO 2H CHROMEN 7 YL]OXY]PROPYL](METHYL)AMINO]METHYL]PHENYL(5 PHENYLPENTYL)CARBAMATE; 4 4 [[(2 OXO 2H CHROMEN 7 YL)OXY]METHYL)] 1H 1,2,3 TRIAZOL 1YL]PHENYL HEPTYLCARBAMATE; 4 [4-[[(2 OXO 2H CHROMEN 7 YL)OXY]METHYL] 1H 1,2,3 TRIAZOL 1YL]PHENYL(5 PHENYLPENTYL)CARBAMATE; 4 [[4 [[(2 OXO 2H CHROMEN 7 YL)OXY]METHYL 1H 1,2,3 TRIAZOL 1YL]METHYL]PHENYL HEPTYLCARBAMATE; 4 [[4 [[(2 OXO 2H CHROMEN 7 YL)OXY]METHYL] 1H 1,2,3 TRIAZOL 1YL]METHYL]PHENYL(5 PHENYLPENTYL)CARBAMATE; ACETYLCHOLINESTERASE; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE; FATTY ACID AMIDASE; NOOTROPIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; AMIDASE; ENZYME INHIBITOR; FATTY-ACID AMIDE HYDROLASE;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; METABOLISM; MOLECULAR MODEL; SYNTHESIS; TUMOR CELL LINE;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMIDOHYDROLASES; BUTYRYLCHOLINESTERASE; CARBAMATES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84978758730     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00609     Document Type: Article

References (51)

1. Prince, M. and Jackson, J. World Alzheimer disease report. Alzheimer's Disease International: London, 2009; pp 25-46.
2. Masters, C. L.; Selkoe, D. J. Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer Disease Cold Spring Harbor Perspect. Med. 2012, 2, a006262 10.1101/cshperspect.a006262
3. Avila, J. Tau phosphorylation and aggregation in Alzheimer's disease pathology FEBS Lett. 2006, 580, 2922-2927 10.1016/j.febslet.2006.02.067
4. Bell, K. F.; Cuello, A. C. Altered synaptic function in Alzheimer's disease Eur. J. Pharmacol. 2006, 545, 11-21 10.1016/j.ejphar.2006.06.045
5. Kanaan, N. M.; Pigino, G. F.; Brady, S. T.; Lazarov, O.; Binder, L. I.; Morfini, G. A. Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system Exp. Neurol. 2013, 246, 44-53 10.1016/j.expneurol.2012.06.003
6. Contestabile, A. The history of the cholinergic hypothesis Behav. Brain Res. 2011, 221, 334-340 10.1016/j.bbr.2009.12.044
7. Weinstock, M. Selectivity of cholinesterase inhibition: Clinical implications for the treatment of Alzheimer's disease CNS Drugs 1999, 12, 307-323 10.2165/00023210-199912040-00005
8. Greig, N. H.; Utsuki, T.; Ingram, D. K.; Wang, Y.; Pepeu, G.; Scali, C.; Yu, Q.-S.; Mamczarz, J.; Holloway, H. W.; Giordano, T.; Chen, D. M.; Furukawa, K.; Sambamurti, K.; Brossi, A.; Lahiri, D. K. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 17213-17218 10.1073/pnas.0508575102
9. Fernandez, J. A.; Rojo, L.; Kuljisa, R. O.; Maccioni, R. B. The damage signals hypothesis of Alzheimer's Disease pathogenesis J. Alzheimer's Dis. 2008, 14, 329-333
10. Frank-Cannon, T. C.; Alto, L. T.; McAlpine, F. E.; Tansey, M. G. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol. Neurodegener. 2009, 4, 47 10.1186/1750-1326-4-47
11. Fagan, S. G.; Campbell, V. A. The influence of cannabinoids on generic traits of neurodegeneration Br. J. Pharmacol. 2014, 171, 1347-1360 10.1111/bph.12492
12. Di Marzo, V. Endocannabinoids: synthesis and degradation Rev. Physiol., Biochem. Pharmacol. 2006, 160, 1-24 10.1007/112-0505
13. Jung, K. M.; Astarita, G.; Yasar, S.; Vasilevko, V.; Cribbs, D. H.; Head, E.; Cotman, C. W.; Piomelli, D. An amyloid β(42)-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease Neurobiol. Aging 2012, 33, 1522-1532 10.1016/j.neurobiolaging.2011.03.012
14. Benito, C.; Nunez, E.; Tolon, R. M.; Carrier, E. J.; Rabano, A.; Hillard, C. J.; Romero, J. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains J. Neurosci. 2003, 23, 11136-11141
15. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases J. Med. Chem. 2008, 51, 347-372 10.1021/jm7009364
16. Morphy, R.; Rankovic, Z. Designing multiple ligands-medicinal chemistry strategies and challenges Curr. Pharm. Des. 2009, 15, 587-600 10.2174/138161209787315594
17. Rampa, A.; Bartolini, M.; Bisi, A.; Belluti, F.; Gobbi, S.; Andrisano, V.; Ligresti, A.; Di Marzo, V. The first dual ChE/FAAH inhibitors: new perspective for Alzheimer's disease? ACS Med. Chem. Lett. 2012, 3, 182-186 10.1021/ml200313p
18. Rampa, A.; Bisi, A.; Valenti, P.; Recanatini, M.; Cavalli, A.; Andrisano, V.; Cavrini, V.; Fin, L.; Buriani, A.; Giusti, P. Acetylcholinesterase inhibitors: synthesis and structure-activity relationships of ω-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)-methyl]-aminoalkoxyheteroaryl derivatives J. Med. Chem. 1998, 41, 3976-3986 10.1021/jm9810046
19. Ellman, G. L.; Courtney, K. D.; Andres, V.; Featherstone, R. M. A new rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 1961, 7, 88-95 10.1016/0006-2952(61)90145-9
20. Wilson, I. B.; Hatch, M. A.; Ginsburg, S. Carbamylation of acetvlcholinesterase J. Biol. Chem. 1960, 235, 2312-2315
21. Wilson, I. B.; Harrison, M. A.; Ginsburg, S. Carbamyl derivatives of acetylcholinesterase J. Biol. Chem. 1961, 236, 1498-1500
22. Bolognesi, M. L.; Bartolini, M.; Cavalli, A.; Andrisano, V.; Rosini, M.; Minarini, A.; Melchiorre, C. Design, synthesis, and biological evaluation of conformationally restricted Rivastigmine analogues J. Med. Chem. 2004, 47, 5945-5952 10.1021/jm049782n
23. Marta, M.; Gatta, F.; Pomponi, M. Physostigmine analogs anticholinesterases: effects of the lengthening of the N-carbamic chain on the inhibition kinetics Biochim. Biophys. Acta, Protein Struct. Mol. Enzymol. 1992, 1120, 262-266 10.1016/0167-4838(92)90246-A
24. Yu, Q.-S.; Holloway, H. W.; Luo, W.; Lahiri, D. K.; Brossi, A.; Greig, N. H. Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine Bioorg. Med. Chem. 2010, 18, 4687-4693 10.1016/j.bmc.2010.05.022
25. Mant, T.; Troetel, W. M.; Imbimbo, B. P. Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers J. Clin. Pharmacol. 1998, 38, 610-617 10.1002/j.1552-4604.1998.tb04467.x
26. Asthana, S.; Greig, N. H.; Hegedus, L.; Holloway, H. H.; Raffaele, K. C.; Schapiro, M. B.; Soncrant, T. T. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease Clin. Pharmacol. Ther. 1995, 58, 299-309 10.1016/0009-9236(95)90246-5
27. Feaster, R. S.; Quinn, D. M. Mechanism-based inhibitors of mammalian cholesterol esterase Methods Enzymol. 1997, 286, 231-252 10.1016/S0076-6879(97)86013-2
28. Mor, M.; Lodola, A.; Rivara, S.; Vacondio, F.; Duranti, A.; Tontini, A.; Sanchini, S.; Piersanti, G.; Clapper, J. R.; King, A. R.; Tarzia, G.; Piomelli, D. Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates J. Med. Chem. 2008, 51, 3487-3498 10.1021/jm701631z
29. Vacondio, F.; Silva, C.; Lodola, A.; Fioni, A.; Rivara, S.; Duranti, A.; Tontini, A.; Sanchini, S.; Clapper, J. R.; Piomelli, D.; Mor, M.; Tarzia, G. Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability ChemMedChem 2009, 4, 1495-1504 10.1002/cmdc.200900120
30. Holt, S.; Nilsson, J.; Omeir, R.; Tiger, G.; Fowler, C. J. Effects of pH on the inhibition of fatty acid amidohydrolase by ibuprofen Br. J. Pharmacol. 2001, 133, 513-520 10.1038/sj.bjp.0704113
31. Lodola, A.; Mor, M.; Rivara, S.; Christov, C.; Tarzia, G.; Piomelli, D.; Mulholland, A. J. Identification of productive inhibitor binding orientation in fatty acid amide hydrolase (FAAH) by QM/MM mechanistic modelling Chem. Commun. 2008, 14, 214-216 10.1039/B714136J
32. Patricelli, M. P.; Lovato, M. A.; Cravatt, B. F. Chemical and mutagenic investigations of fatty acid amide hydrolase: evidence for a family of serine hydrolases with distinct catalytic properties Biochemistry 1999, 38, 9804-9812 10.1021/bi990637z
33. Patricelli, M. P.; Cravatt, B. F. Clarifying the catalytic roles of conserved residues in the amidase signature family J. Biol. Chem. 2000, 275, 19177-19184 10.1074/jbc.M001607200
34. Bracey, M. H.; Hanson, M. A.; Masuda, K. R.; Stevens, R. C.; Cravatt, B. F. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling Science 2002, 298, 1793-1796 10.1126/science.1076535
35. Nicolet, Y.; Lockridge, O.; Masson, P.; Fontecilla-Camps, J. C.; Nachon, F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products J. Biol. Chem. 2003, 278, 41141-41147 10.1074/jbc.M210241200
36. Brus, B.; Košak, U.; Turk, S.; Pišlar, A.; Coquelle, N.; Kos, J.; Stojan, J.; Colletier, J. P.; Gobec, S. Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor J. Med. Chem. 2014, 57, 8167-8179 10.1021/jm501195e
37. Rizzo, S.; Cavalli, A.; Ceccarini, L.; Bartolini, M.; Belluti, F.; Bisi, A.; Andrisano, V.; Recanatini, M.; Rampa, A. Structure-activity relationships and binding mode in the human acetylcholinesterase active site of pseudo-irreversible inhibitors related to xanthostigmine ChemMedChem 2009, 4, 670-679 10.1002/cmdc.200800396
38. Wieckowska, A.; Bajda, M.; Guzior, N.; Malawska, B. Novel alkyl- and arylcarbamate derivatives with N-benzylpiperidine and N-benzylpiperazine moieties as cholinesterasesinhibitors Eur. J. Med. Chem. 2010, 45, 5602-5611 10.1016/j.ejmech.2010.09.010
39. Denizot, F.; Lang, R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability J. Immunol. Methods 1986, 89, 271-277 10.1016/0022-1759(86)90368-6
40. Ghosh, A. K.; Brindisi, M. Organic carbamates in drug design and medicinal chemistry J. Med. Chem. 2015, 58, 2895-2940 10.1021/jm501371s
41. Pisani, L.; Catto, M.; Giangreco, I.; Leonetti, F.; Nicolotti, O.; Stefanachi, A.; Cellamare, S.; Carotti, A. Design, synthesis, and biological evaluation of coumarin derivatives tethered to an edrophonium-like fragment as highly potent and selective dual binding site acetylcholinesterase inhibitors ChemMedChem 2010, 5, 1616-1630 10.1002/cmdc.201000210
42. Maestro, version 9.8; Schrödinger, LLC: New York, NY, 2014.
43. LigPrep, version 3.0; Schrödinger, LLC: New York, NY, 2014.
44. Schrödinger Suite, 2014-2 Protein Preparation Wizard.
45. Epik, version 2.8; Schrödinger, LLC: New York, NY, 2014.
46. Impact, version 6.3; Schrödinger, LLC: New York, NY, 2014.
47. Prime, version 3.6; Schrödinger, LLC: New York, NY, 2014.
48. Glide, version 6.3; Schrödinger, LLC: New York, NY, 2014.
49. Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids J. Am. Chem. Soc. 1996, 118, 11225-11236 10.1021/ja9621760
50. Macromodel, version 10.4; Schrödinger, LLC: New York, NY, 2014.
51. Prime, version 3.6; Schrödinger, LLC: New York, NY, 2014.